Symptomatic Vitreomacular Adhesion (VMA)
Also known as: Symptomatic Vitreomacular Adhesion
| Drug | Drug Name | Drug Description |
|---|---|---|
| DB08888 | Ocriplasmin | A proteolytic enzyme used to treat symptomatic vitreomacular adhesion by dissolving the protein matrix responsible for the adhesion between the vitreous and macula. |
| Drug | Drug Name | Target | Type |
|---|---|---|---|
| DB08888 | Ocriplasmin | Alpha-2-macroglobulin | target |
| DB08888 | Ocriplasmin | Alpha-2-antiplasmin | target |
| DB08888 | Ocriplasmin | Fibronectin | target |
| Drug | Drug Name | Phase | Status | Count |
|---|---|---|---|---|
| DB08888 | Ocriplasmin | 3 | Completed | 1 |
| DB08888 | Ocriplasmin | Not Available | Completed | 1 |